Botulinum toxin treatment for functional disability induced by essential tremor
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This study aimed to improve botulinum toxin's (BTX) efficacy and to reduce its unwanted effects in the treatment of functional disability due to essential tremor (ET) of the hand. Twenty patients with disabling ET, not responding to conventional pharmacological therapy, were enrolled in this open-label study. Activities of daily living self-questionnaire (ADLS) and severity tremor scale (STS) were used to establish patients' functional disability and tremor severity. Accelerometry and surface electromyography were used to identify the arm muscles with tremorogenic activity during impaired positions. Global rating was used to measure treatment efficacy and unwanted effects. BTX type A was injected into the muscles principally responsible for impaired positions. After BTX treatment, there was a significant reduction in both severity and functional rating scales scores (ADLS and STS) and of tremor amplitude as measured with accelerometry and EMG. Adverse effects were limited to a slight third finger extension weakness in 15% of patients. BTX injections are effective and safe in reducing disability due to ET, if based on the criterion of functional selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This approach has been used successfully with the advantage of providing very targeted relief (46–51).”
From Could Wearable and Mobile Technology Improve the Management of Essential Tremor? (2018) · cites this paper as [50]
Citations
Cites
Bain, P. G., Findley, L. J., Atchison, P., Behari, M., Vidailhet, M., Gresty, M., Rothwell, J. C., Thompson, P. D., & Marsden, C. D. (1993) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.8.868 · Cited by 437
Louis, E. D., Ottman, R., & Allen Hauser, W. (1998) · Movement Disorders · doi:10.1002/mds.870130105 · Cited by 424 · cited 1×
“Only 50%-60% of patients with ET, the most common movement disorder [14], improves functional disability pharmacologically.”
BackgroundJankovic, J., Schwartz, K., Clemence, W., Aswad, A., & Mordaunt, J. (1996) · Movement Disorders · doi:10.1002/mds.870110306 · Cited by 235 · cited 4×
“The use of botulinum toxin type A (BTX) for the treatment of hand tremor has now been established [1-5].”
BackgroundMethodInfluentialBotulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
Girlanda, P., Vita, G., Nicolosi, C., Milone, S., & Messina, C. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.9.844 · Cited by 184
Advances in processing of surface myoelectric signals: Part 1
Merletti, R., & Conte, L. L. (1995) · Medical & Biological Engineering & Computing · doi:10.1007/bf02510518 · Cited by 158
Botulinum toxin treatment of tremors
Jankovic, J., & Schwartz, K. (1991) · Neurology · doi:10.1212/wnl.41.8.1185 · Cited by 152
“Off” painful dystonia in Parkinson's disease treated with botulinum toxin
Pacchetti, C., Albani, G., Martignoni, E., Godi, L., Alfonsi, E., & Nappi, G. (1995) · Movement Disorders · doi:10.1002/mds.870100317 · Cited by 116
Self-citationBotulinum toxin a injections for the treatment of hand tremors
Trosch, R. M., & Pullman, S. L. (1994) · Movement Disorders · doi:10.1002/mds.870090604 · Cited by 111
Pharmacologic treatment of essential tremor.
Koller, W. C., Hristova, A. H., & Brin, M. F. (2000) · PubMed · Cited by 79
Advances in processing of surface myoelectric signals: Part 2
Conte, L. L., & Merletti, R. (1995) · Medical & Biological Engineering & Computing · doi:10.1007/bf02510519 · Cited by 59
Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp
Sheean, G. L., Murray, N. M. F., & MARSDEN, C. D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91212-6 · Cited by 38
Cited by
Essential tremor: diagnosis and management
Shanker, V. (2019) · BMJ · doi:10.1136/bmj.l4485 · Cited by 182
Botulinum Toxin in Movement Disorders: An Update
Anandan, C., & Jankovic, J. J. (2021) · Toxins · doi:10.3390/toxins13010042 · Cited by 171
Benefits and Risks of Pharmacological Treatments for Essential Tremor
Lyons, K. E., Pahwa, R., Comella, C. L., Eisa, M. S., Elble, R. J., Fahn, S., Jankovic, J., Juncos, J. L., Koller, W. C., Ondo, W. G., et al. (2003) · Drug Safety · doi:10.2165/00002018-200326070-00003 · Cited by 103
Zappia, M., Albanese, A., Bruno, E., Colosimo, C., Filippini, G., Martinelli, P., Nicoletti, A. S. Q., Quattrocchi, G., Abbruzzese, G., Berardelli, A., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6628-x · Cited by 100
Botulinum Toxin in Parkinson Disease Tremor
Mittal, S. O., Machado, D., Richardson, D., Dubey, D., & Jabbari, B. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.06.010 · Cited by 72
Metadata
- Authors
- Pacchetti, C., Mancini, F., Bulgheroni, M., Zangaglia, R., Cristina, S., Sandrini, G., & Nappi, G.
- Affiliations
- University of Pavia (IT)
- Sapienza University of Rome (IT)
- Venue
- Neurological Sciences
- Published
- 2000-12-01
- Volume
- 21
- Issue
- 6
- Pages
- 349-353
- ISSN
- 1590-1874 (ISSN-L)
- 1590-3478
- OpenAlex
- W2022514226
- Cited by
- 48
- References
- 11
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 1 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 2 · 2012: 2
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neurological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Keywords
- botulinum toxin type A, essential tremor, hand tremor, functional disability, activities of daily living, tremor severity, surface electromyography, accelerometry, adverse effects, treatment efficacy
- MeSH terms
- Aged, Arm, Disability Evaluation, Electromyography, Female, Humans, Male, Middle Aged, Neuromuscular Agents, Surveys and Questionnaires, Treatment Outcome, Patient Satisfaction, Muscle, Skeletal, Botulinum Toxins, Type A, Recovery of Function, Essential Tremor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.